Title:
HETEROCYCLIC COMPOUND AS RECEPTOR INTERACTING PROTEIN 1(RIP1) KINASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2020/043173
Kind Code:
A1
Abstract:
Provided in the present invention is a heterocyclic compound as a receptor interacting protein 1(RIP1) kinase inhibitor. In particular, provided in the present invention are a compound as shown in formula I, or pharmaceutically acceptable salts thereof, or pharmaceutically acceptable solvates thereof. The compound of formula I has an efficient and high selective inhibiting effect for protein kinase (e.g. RIP1).
Inventors:
WANG NENGHUI (CN)
Application Number:
PCT/CN2019/103367
Publication Date:
March 05, 2020
Filing Date:
August 29, 2019
Export Citation:
Assignee:
NINGBO WENDA PHARMA TECHNOLOY LTD (CN)
International Classes:
C07D413/14; A61K31/422; A61P1/04
Domestic Patent References:
| WO2018092089A1 | 2018-05-24 | |||
| WO2019130230A1 | 2019-07-04 | |||
| WO2017096301A1 | 2017-06-08 | |||
| WO2017096301A1 | 2017-06-08 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: